Saxagliptin Triple Oral Therapy

Summary

The purpose of this study is to determine whether the addition of saxagliptin to a patient's combination treatment of metformin and sulfonylurea for a 24 week period will provide better control of the patient's type 2 diabetes and will be well tolerated.

Timeline

Start

2010-06

Primary completion

2011-06

Completion

2011-06

Outcome

Met primary endpoint

registry Arm 1 - SAXAGLIPTIN vs Arm 2 - PLACEBO; p <0.0001; Mean Difference (Final Values) -0.66 (95% CI -0.86 to -0.47) NCT01128153 ↗

Drugs

Indications